Online Supplement. Relationship Between OSA Clinical Phenotypes and CPAP Treatment Outcomes

Similar documents
The Effect of Patient Neighbourhood Income Level on the Purchase of Continuous Positive Airway

Diagnostic Accuracy of the Multivariable Apnea Prediction (MAP) Index as a Screening Tool for Obstructive Sleep Apnea

Appendix 1. Practice Guidelines for Standards of Adult Sleep Medicine Services

Polysomnography (PSG) (Sleep Studies), Sleep Center

(To be filled by the treating physician)

RESEARCH PACKET DENTAL SLEEP MEDICINE

In-Patient Sleep Testing/Management Boaz Markewitz, MD

The most accurate predictors of arterial hypertension in patients with Obstructive Sleep Apnea Syndrome

Sleep Apnea: Vascular and Metabolic Complications

Shyamala Pradeepan. Staff Specialist- Department of Respiratory and Sleep Medicine. John Hunter Hospital. Conjoint lecturer University of New Castle.

A Deadly Combination: Central Sleep Apnea & Heart Failure

DECLARATION OF CONFLICT OF INTEREST

Obstructive sleep apnoea How to identify?

Simple diagnostic tools for the Screening of Sleep Apnea in subjects with high risk of cardiovascular disease

International Journal of Scientific & Engineering Research Volume 9, Issue 1, January ISSN

Medicare CPAP/BIPAP Coverage Criteria

Mario Kinsella MD FAASM 10/5/2016

Emerging Nursing Roles in Collaborative Management of Sleep Disordered Breathing and Obstructive Sleep Apnoea

Prediction of sleep-disordered breathing by unattended overnight oximetry

Year in Review. Outline of Lecture

The Familial Occurrence of Obstructive Sleep Apnoea Syndrome (OSAS)

The STOP-Bang Equivalent Model and Prediction of Severity

Outline. Major variables contributing to airway patency/collapse. OSA- Definition

Sleep and the Heart. Physiologic Changes in Cardiovascular Parameters during Sleep

Sleep and the Heart. Rami N. Khayat, MD

Circadian Variations Influential in Circulatory & Vascular Phenomena

Upper Airway Stimulation for Obstructive Sleep Apnea

Sleep and the Heart Reversing the Effects of Sleep Apnea to Better Manage Heart Disease

Questions: What tests are available to diagnose sleep disordered breathing? How do you calculate overall AHI vs obstructive AHI?

OBSTRUCTIVE SLEEP APNEA and WORK Treatment Update

QUESTIONS FOR DELIBERATION

FAQ CODING & REIMBURSEMENT. WatchPAT TM Home Sleep Test

Association of Nocturnal Cardiac Arrhythmias with Sleep- Disordered Breathing

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

11/13/2017. Jeremy Tabak MD, FAASM Medical Director Baptist Hospital Sleep Lab Medical Director Baptist Sleep Lab at Galloway

The use of overnight pulse oximetry for obstructive sleep apnoea in a resource poor setting in Sri Lanka

Clinical Trials in OSA

CPAP The Treatment of Choice for Patients with OSA

PEDIATRIC OBSTRUCTIVE SLEEP APNEA (OSA)

Is CPAP helpful in severe Asthma?

Introducing the WatchPAT 200 # 1 Home Sleep Study Device

Index SLEEP MEDICINE CLINICS. Note: Page numbers of article titles are in boldface type.

Sleep Disordered Breathing: Beware Snoring! Dr T A McDonagh Consultant Cardiologist Royal Brompton Hospital London. UK

Diabetes & Obstructive Sleep Apnoea risk. Jaynie Pateraki MSc RGN

Management of OSA in the Acute Care Environment. Robert S. Campbell, RRT FAARC HRC, Philips Healthcare May, 2018

Coding for Sleep Disorders Jennifer Rose V. Molano, MD

Sleepiness in Patients with Moderate to Severe Sleep-Disordered Breathing

Joel Reiter*, Bashar Zleik, Mihaela Bazalakova, Pankaj Mehta, Robert Joseph Thomas

Obstructive sleep apnea (OSA) is characterized by. Quality of Life in Patients with Obstructive Sleep Apnea*

Goals Session Putting it all Together

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

Overnight fluid shifts in subjects with and without obstructive sleep apnea

Treatment of Obstructive Sleep Apnea (OSA)

Sleep Studies: Attended Polysomnography and Portable Polysomnography Tests, Multiple Sleep Latency Testing and Maintenance of Wakefulness Testing

The Epworth Sleepiness Scale (ESS), which asks an individual

Dr Alireza Yarahmadi and Dr Arvind Perathur Mercy Medical Center - Winter Retreat Des Moines February 2012

Obstructive Sleep Apnea

Obstructive Sleep Apnea in Truck Drivers

Sleep Apnea in Women: How Is It Different?

Sleep Diordered Breathing (Part 1)

PEDIATRIC PAP TITRATION PROTOCOL

Critical Review Form Diagnostic Test

The Agony or the Ecstasy. Familiar?

Healthy Sleep. Frederick Tolle, M.D., dabsm Community Health Network

PORTABLE OR HOME SLEEP STUDIES FOR ADULT PATIENTS:

Does AHI Value Enough for Evaluating the Obstructive Sleep Apnea Severity?

SLEEP DISORDERED BREATHING The Clinical Conditions

Associations Between Subjective Night Sweats and Sleep Study Findings

Evaluation of the Brussells Questionnaire as a screening tool

Sleep Medicine. Paul Fredrickson, MD Director. Mayo Sleep Center Jacksonville, Florida.

Pre-Operative Services Teaching Rounds 11 March 2011

Outcome Measures in OSA Defining Our Treatment Goal. Defining common outcome metrics in OSA Al-Shawwa Sleep Med Rev 2008

Effect of mandibular advancement therapy on inflammatory and metabolic biomarkers

The Epworth Sleepiness Scale (ESS) was developed by Johns

WHAT YOU NEED TO KNOW ABOUT SLEEP APNEA

Sleep Bruxism and Sleep-Disordered Breathing

A new beginning in therapy for women

Association of Nocturnal Arrhythmias with. Sleep-Disordered Breathing: The Sleep Heart Health Study. On Line Supplement

Nasal pressure recording in the diagnosis of sleep apnoea hypopnoea syndrome

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Treatment-related changes in sleep apnea syndrome in patients with acromegaly: a prospective study

Inspire Therapy for Sleep Apnea

Study of Prevalence of OSA in VIET NAM EPSASIE STUDY

New Government O2 Criteria and Expert Panel. Jennifer Despain, RPSGT, RST, AS

Sleep Disorders and the Metabolic Syndrome

Polycystic Ovarian Syndrome and Obstructive Sleep Apnea: Poor Bedpartners. M. Begay, MD UNM Sleep Medicine Fellow 01/31/2017

Effect of two types of mandibular advancement splints on snoring and obstructive sleep apnoea

What is SDB? Obstructive sleep apnea-hypopnea syndrome (OSAHS)

DECISION AND ORDER. After due notice, a telephone hearing was held on. , Medical Director, also testified as a witness for the MHP.

Inspire Therapy for Sleep Apnea

SLEEP APNOEA DR TAN KAH LEONG ALVIN CO-DIRECTOR SLEEP LABORATORY SITE CHIEF SDDC (SLEEP) DEPARTMENT OF OTORHINOLARYNGOLOGY, HEAD & NECK SURGERY

Sleep Disordered Breathing

PHYSICIAN EVALUATION AMONG DENTAL PATIENTS WHO SCREEN HIGH-RISK FOR SLEEP APNEA. Kristin D. Dillow

Polysomnography and Sleep Studies

Removal of the CPAP Therapy Device During Sleep and Its Association With Body Position Changes and Oxygen Desaturations

THN. Sleep Therapy Study. ImThera. Information for Participants. Caution: Investigational device. Limited by United States law to investigational use.

Obstructive sleep apnea (OSA) is the periodic reduction

José Haba-Rubio, MD; Jean-Paul Janssens, MD; Thierry Rochat, MD, PhD; and Emilia Sforza, MD, PhD

EFFICACY OF MODAFINIL IN 10 TAIWANESE PATIENTS WITH NARCOLEPSY: FINDINGS USING THE MULTIPLE SLEEP LATENCY TEST AND EPWORTH SLEEPINESS SCALE

Transcription:

Relationship Between OSA Clinical Phenotypes and CPAP Treatment Outcomes Frédéric Gagnadoux, MD, PhD; Marc Le Vaillant, PhD; Audrey Paris, MD, PhD; Thierry Pigeanne, MD; Laurence Leclair-Visonneau, MD; Acya Bizieux-Thaminy, MD; Claire Alizon, MD; Marie-Pierre Humeau, MD; Xuan-Lan Nguyen, MD; Béatrice Rouault, MD; Wojciech Trzepizur, MD, PhD; Nicole Meslier, MD; on behalf of the Institut de Recherche en Santé Respiratoire des Pays de la Loire Sleep Cohort Group* CHEST 2016; 149(1):288-290 2016 AMERICAN COLLEGE OF CHEST PHYSICIANS. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: 10.1016/j.chest.2015.09.032

e-appendix 1. ABBREVIATIONS: AHI: apnea-hypopnea index; CVD: cardiovascular diseases; CPAP: continuous positive airway pressure; EDS: Excessive daytime sleepiness; ESS: Epworth Sleepiness Scale; HR-QOL: Health-related quality of life; PSG: polysomnography; QD2A: 13-item self-rated Pichot depression scale; SDB: sleep-disordered breathing METHODS Design and study population This prospective cohort study was conducted on the Institut de Recherche en Santé Respiratoire des Pays de la Loire [IRSR] sleep cohort. Since 15 May 2007, consecutive patients 18 years investigated for clinical suspicion of OSA in 7 centres from the West of France are eligible for inclusion in the IRSR sleep cohort. Approval was obtained from the University of Angers ethics committee and from the "Comité Consultative sur le Traitement de l Information en matière de Recherche dans le domaine de la Santé [C.C.T.I.R.S.] (07.207bis). The database is anonymous and complies with the restrictive requirements of the "Commission Nationale Informatique et Liberté [C.N.I.L.], the French information technology, and personal data protection authority. All patients included in the IRSR sleep cohort gave their written informed consent. Between 15 May 2007 and 1 st December 2014, patients from the IRSR sleep cohort with an AHI 15, indicating moderate-to-severe OSA, were included in the cross-sectional cluster analysis to identify phenotypes. Patients in whom CPAP had been prescribed for at least 6 months with available follow-up data on CPAP adherence, daytime sleepiness and quality of life were included in the analysis of CPAP outcomes. Baseline assessment Questionnaires The following sleep-related symptoms were considered to be present when they occurred at least 3 times a week: loud snoring, stopped breathing during sleep, unrested upon waking, headache upon waking. A complaint of insomnia was recorded when patients reported frequent difficulty falling asleep and/or difficulty staying asleep and/or early final awakening. Excessive daytime sleepiness (EDS) was defined by an Epworth Sleepiness Score (ESS)>10 1. Symptoms of depression were defined by a QD2A depression score 7 2,3. Health-related quality of life (HR- QOL) was assessed using the Outcomes Study 36-item short-form (SF-36) 4. Socioeconomic status (SES) was described by the following variables: marital status (married or living as a couple / living alone); employment status (employed full time or part time / retired /

unemployed); and educational attainment as determined by the age at which the patient left full-time education ( 18 / >18 years) 5. Assessment of co morbidities Obesity was defined by a body mass index (BMI) 30 kg/m 2. Hypertension (HTN) and diabetes were defined as a physician diagnosis combined with treatment with appropriate medication. Co morbid cardiovascular disease (CVD) was defined as a physician diagnosis of 1 of the following CVD: ischaemic heart disease, cardiac arrhythmia, congestive heart failure and stroke. Sleep recordings OSA was diagnosed by overnight polysomnography (PSG) or overnight respiratory recording. Overnight PSG was performed with continuous recording of the following channels: electroencephalogram, electrooculogram, chin electromyogram, arterial oxygen saturation, nasal-oral airflow (pressure cannula and tracheal sounds), electrocardiogram, chest and abdominal wall motion, and body position. Overnight respiratory recordings were performed with continuous recording of arterial oxygen saturation, nasal-oral airflow, chest and abdominal wall motion, and body position. Respiratory events were scored manually using recommended criteria 6. CPAP initiation and follow-up According to French guidelines, CPAP was prescribed in patients with OSA symptoms and either an apnea-hypopnea index (AHI) 30 or an AHI between 15 and <30 with severe EDS and/or severe CVD co morbidities. At 6 months, patients were reviewed in the outpatient clinic by the sleep specialist and filled in the ESS and SF-36 questionnaire. Objective data concerning CPAP adherence were downloaded from the internal memory of the device. Statistical analysis Latent class analysis (LCA) was conducted to identify OSA clusters. LCA is a statistical method for finding subgroups of related cases from multivariate discrete data based on the patterns of their associated variables 7,8. Thirteen clinically relevant dichotomized variables were entered in the LCA, including demographic and anthropometric data, sleep-related symptoms, complaint of insomnia, EDS, depressive symptoms and co morbidities. The most appropriate number of clusters was determined by examining commonly used criteria, including the Akaike Information Criterion (AIC), the Bayesian Information Criterion (BIC), the sample size-adjusted BIC (SSABIC), the Lo-Mendell-Rubin Likelihood Ratio Test (LMR-LRT), and the entropy 7. To graphically display the OSA clusters identified by LCA, we plotted the prevalence of each variable in each cluster on a colour intensity scale spanning from yellow (prevalence of 0) to red

(prevalence of 100) 7. The relative relevance of each variable to the separation into clusters was evaluated by using Chi 2 values. Differences among clusters with regards to SES and sleep recordings data were also examined using Chi-squared test or ANOVA, as appropriate. To validate the clinical relevance of OSA clusters identified by LCA, treatment outcomes were compared across clusters in the subgroup of patients in whom CPAP had been prescribed for at least 6 months with available follow-up data. The profile of the distribution of the variables across the clusters identified by LCA was compared in the total sample and in the CPAP follow-up subgroup, and the individual agreement in the assigned cluster was tested by means of Kappa statistics. The primary outcome variable was the success of CPAP treatment at 6 months followup, as defined by mean daily use of the device 4h and either a decrease in ESS 4 points in patients with baseline value 11 and/or an increase of at least 7 points in the energy/vitality component score of the SF-36 questionnaire regardless of baseline ESS value. A logistic regression procedure was conducted to model the association between OSA clusters and the success of CPAP treatment at 6 months follow-up. Unadjusted and adjusted odds ratio (OR) (95 confidence intervals [CI]) for CPAP treatment success according to OSA cluster were calculated. To adjust for potential confounders, the following covariates that are likely to interfere with CPAP outcomes were progressively entered in the multivariate logistic regression analysis: SES, AHI and ESS. All statistical analyses were performed with SAS software (SAS/STAT Package 2002 2003 by SAS Institute Inc., Cary, NC, USA) and MPlus V.7.2 for LCA. A 2-tailed p value < 0.05 was considered significant. RESULTS A flow diagram is presented in e-figure 1. On 1 st December 2014, 9,907 patients had been enrolled in the IRSR sleep cohort and 3,924 of them had an AHI value < 15. A total of 5,983 patients with moderate-to-severe OSA were included in the cross-sectional analysis. Among 4,224 patients in whom CPAP had been prescribed for at least 6 months, 401 had no available CPAP adherence data at 6 months and 733 had missing follow-up data regarding EDS and/or HR-QOL; 3,090 patients were therefore included in the CPAP outcomes analysis. As expected, patients included in the CPAP outcomes analysis had slightly more severe disease than the entire baseline cohort in terms of symptoms, AHI and co morbidities (e-table 1).

e-table 2 shows the distribution of the 13 variables across the 5 OSA clusters in the entire baseline population. As shown in e-table 3, significant differences were observed between distinct OSA clusters regarding SES and sleep recording data. e-figure 1: Flow diagram of subjects during the study. IRSR, Institut de Recherche en Santé Respiratoire des Pays de la Loire; OSA, obstructive sleep apnoea; AHI, apnoea-hypopnoea index.

e-table 1: Comparison of the entire baseline population with the CPAP follow-up population Variables Entire baseline population (n=5,983) CPAP follow-up population (n=3,090) p value Age, years 60.1 (12.9) 60.9 (12.3) <0.0001 Female, 28.9 28.0 0.1238 BMI, kg/m 2 31.7 (6.7) 32.3 (6.6) <0.0001 Epworth sleepiness 9.9 (5.0) 10.3 (5.0) <0.0001 score QD2A depression score 3.7 (3.4) 3.8 (3.4) 0.0010 SF-36 energy/vitality 47.2 (20.7) 46.3 (20.7) 0.0002 score AHI 41.0 (20.4) 44.6 (20.4) <0.0001 Comorbidities HTN, 41.1 43.0 0.0029 CVD, 19.5 19.9 0.3247 Diabetes, 17.6 19.0 0.0034 Results expressed as mean (standard deviation) unless otherwise indicated. BMI, body mass index; AHI, apnoea-hypopnoea index; HTN, hypertension; CVD, cardiovascular disease

e-table 2: Description of the five obstructive sleep apnea clusters in the entire baseline population (n=5,983) All (n=5,9 83) 1 (n=848 ) Cluste r 2 (n=90 0) 3 (n=1,0 90) 4 (n=1,9 19) 5 (n=1,2 27) Chi 2 value s Obesity, 54.4 84.7 65.2 53.6 30.3 64.4 844 Age>65 years, 35.6 42.6 59.0 3.6 19.8 66.7 1,44 8 Female, 28.9 90.2 7.7 38.3 16.6 13.0 2,08 9 Complaint 23.5 40.5 13.0 2.9 32.4 21.5 500 of insomnia, Loud 79.8 74.4 89.9 92.1 82.3 60.0 433 snoring, Stopped 62.8 41.0 81.5 69.1 69.7 47.4 462 breathing, Unrested upon waking, 72.1 92.3 98.0 100.0 66.3 21.1 2,32 3 Headache upon waking, Depressive symptoms, 37.5 67.5 32.7 68.2 28.7 6.4 1,33 2 20.9 36.9 41.2 34.5 7.2 2.2 949 EDS, 44.2 25.6 66.3 97.6 29.5 16.4 2,08 5 HTN, 41.1 64.3 79.6 13.0 6.3 74.8 2,50 7 CVD, 19.5 13.4 53.8 3.6 3.5 37.6 1,43 0 Diabetes, 17.6 31.5 38.5 4.2 0.0 31.0 1,03 5 EDS, excessive daytime sleepiness; HTN, hypertension; CVD, cardiovascular disease *Chi 2 values corresponded to the sum of the squared difference between observed and expected data, divided by the expected data in all possible categories

e-table 3: Differences in socioeconomic status and sleep recordings data across the five obstructive sleep apnoea clusters (n=5,983) 1 (n=848) 2 (n=900) 3 (n=1,090) 4 (n=1,919) 5 (n=1,227) p value Socioeconomic status Married or 66.3 79.2 77.0 83.8 81.8 <0.0001 living as a couple, Left full-time 78.5 71.7 57.9 60.3 73.3 <0.0001 education < 18 years, Employment status Employed, 33.9 25.5 70.4 62.9 23.1 <0.0001 Retired, 47.8 63.5 11.1 26.5 71.6 Other, 18.3 11.0 18.5 10.6 5.3 Sleep recording data AHI, events - 1 39.8 (19.9) 46.2 (20.5) 41.4 (22.7) 37.9 (19.2) 42.5 (19.4) <0.0001 Mean SaO 2 92.0 (2.6) 91.6 (2.7) 92.5 (2.9) 92.9 (2.2) 91.7 (2.5) <0.0001 3 ODI, 41.3 32.7 29.0 36.5 <0.0001 events -1 (22.2) (23.7) (26.2) (22.1) (22.0) Time with SaO 2 <90, 17.5 (23.3) 21.3 (22.1) 13.9 (20.8) 10.2 (16.6) 20.7 (22.9) <0.0001 Total sleep time, min N3 sleep*, REM sleep*, Arousal index*, events -1 404.1 (83.1) 22.8 (9.7) 17.1 (7.0) 29.9 (15.2) 402.2 (74.0) 20.0 (9.9) 16.7 (7.0) 35.5 (18.8) 419.9 (70.4) 414.7 (75.8) 390.5 (88.7) <0.0001 22.3 (9.3) 21.2 (8.8) 22.0 (10.3) 0.0049 18.4 (7.4) 19.1 (6.9) 18.1 (7.0) <0.0001 31.6 (17.0) 33.3 (16.8) 34.0 (17.1) 0.0010 AHI, apnea-hypopnea index; SaO 2, oxygen saturation; ODI, oxygen desaturation index; Data are expressed as mean (SD) or percentages; * data available for 2,103 patients

The distribution of the 13 variables across the 5 OSA clusters identified by LCA in the CPAP follow-up population is described in e-figure e-figure 2: Prevalence of each variable according to the clusters identified by Latent Class Analysis in patients include in the CPAP outcomes analysis (n=3,090). Each coloured line represents a variable with prevalence ranging from 0 (yellow) to 100 (red). Only slight although statistically significant differences were observed between clusters regarding CPAP adherence at 6 months with 75.8 to 85.5 of patients using CPAP at least 4 hours per night in clusters 3 and 5, respectively (e-table 4). Overall, 42.3 of patients met the criterion for success of CPAP treatment with marked differences between clusters. The lowest and highest rates of CPAP treatment success were observed in cluster 5 (25.7) and cluster 3 (57.6), respectively.

e-table 4: CPAP treatment outcomes across the five obstructive sleep apnoea clusters CPAP adherence Daily CPAP use, h Daily CPAP use 4h, Reduction in EDS*, Improvemen t of QOL**, CPAP treatment success 1 (n=455 ) Cluste r 2 (n=49 9) Cluste r 3 (n=61 5) 4 (n=905 ) Cluste r 5 (n=61 6) Whole (n=3,0 90) p value 5.8 (2.1) 5.9 (2.1) 5.5 (2.0) 5.6 (2.0) 6.0 (1.9) 5.7 (2.0) <0.00 01 80.5 80.7 75.8 79.5 85.5 80.3 0.002 6 45.0 62.8 67.3 40.9 26.1 47.7 <0.00 01 51.1 47.6 64.2 46.9 31.6 48.2 <0.00 01 37.8 54.1 57.6 39.0 25.7 42.3 <0.00 01 Data are expressed as mean (SD) or percentages; EDS, Excessive daytime sleepiness; QOL, quality of life * Decrease in Epworth score of at least 4 points in patients with baseline value 11 ** Increase of at least 7 points in the energy/vitality component score of the SF-36 questionnaire regardless of baseline Epworth score

References 1 Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991; 14(6):540-545. 2 de Bonis M, Lebeaux MO, de Boeck P, Simon M, Pichot P. Measuring the severity of depression through a self-report inventory. A comparison of logistic, factorial and implicit models. J Affect Disord. 1991; 22(1-2):55-64. 3 Gagnadoux F, Le Vaillant M, Goupil F, et al. Depressive symptoms before and after longterm CPAP therapy in patients with sleep apnea. Chest. 2014; 145(5):1025-1031. 4 Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473-483. 5 Gagnadoux F, Le Vaillant M, Goupil F, et al. Influence of marital status and employment status on long-term adherence with continuous positive airway pressure in sleep apnea patients. PLoS One. 2011; 6(8):e22503. 6 Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999; 22(5):667-689. 7 Sipsma HL, Falb KL, Willie T, et al. Violence against Congolese refugee women in Rwanda and mental health: a cross-sectional study using latent class analysis. BMJ Open. 2015; 5(4):e006299. 8 Ye L, Pien GW, Ratcliffe SJ, et al. The different clinical faces of obstructive sleep apnoea: a cluster analysis. Eur Respir J. 2014; 44(6):1600-1607. 152189